These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35792390)

  • 1. Provoked seizures at the onset of progressive disease contribute to diagnosis delay - A tertiary center experience in a cohort of 22 children with CLN2.
    Kravljanac R; Vucetic Tadic B
    Eur J Paediatr Neurol; 2022 Sep; 40():1-4. PubMed ID: 35792390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset childhood neuronal ceroid lipofuscinosis: Early clinical and electroencephalographic markers.
    Beltrán L; Valenzuela GR; Loos M; Vargas R; Lizama R; Spinsanti P; Caraballo R
    Epilepsy Res; 2018 Aug; 144():49-52. PubMed ID: 29778029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
    Nickel M; Gissen P; Greenaway R; Cappelletti S; Hamborg C; Ragni B; Ribitzki T; Schulz A; Tondo I; Specchio N
    Neuropediatrics; 2023 Dec; 54(6):402-406. PubMed ID: 37329878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provoked seizures might lead to a significant diagnosis delay in CLN2.
    Rener-Primec Z
    Eur J Paediatr Neurol; 2022 Sep; 40():A4-A5. PubMed ID: 36050257
    [No Abstract]   [Full Text] [Related]  

  • 6. Next-generation sequencing in childhood-onset epilepsies: Diagnostic yield and impact on neuronal ceroid lipofuscinosis type 2 (CLN2) disease diagnosis.
    Gall K; Izzo E; Seppälä EH; Alakurtti K; Koskinen L; Saarinen I; Singh A; Myllykangas S; Koskenvuo J; Alastalo TP
    PLoS One; 2021; 16(9):e0255933. PubMed ID: 34469436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.
    Nickel M; Simonati A; Jacoby D; Lezius S; Kilian D; Van de Graaf B; Pagovich OE; Kosofsky B; Yohay K; Downs M; Slasor P; Ajayi T; Crystal RG; Kohlschütter A; Sondhi D; Schulz A
    Lancet Child Adolesc Health; 2018 Aug; 2(8):582-590. PubMed ID: 30119717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease.
    Leal-Pardinas F; Truty R; McKnight DA; Johnson B; Morales A; Bristow SL; Yar Pang T; Cohen-Pfeffer J; Izzo E; Sankar R; Koh S; Wirrell EC; Millichap JJ; Aradhya S
    Epilepsia; 2022 Jul; 63(7):e68-e73. PubMed ID: 35474188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease.
    Specchio N; Bellusci M; Pietrafusa N; Trivisano M; de Palma L; Vigevano F
    Epilepsia; 2017 Aug; 58(8):1380-1388. PubMed ID: 28632327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling neuronal ceroid lipofuscinosis type 2 (CLN2) disease: A tertiary center experience for determinants of diagnostic delay.
    Ardicli D; Haliloglu G; Gocmen R; Gunbey C; Topcu M
    Eur J Paediatr Neurol; 2021 Jul; 33():94-98. PubMed ID: 34119739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.
    Augustine EF; Adams HR; Beck CA; Vierhile A; Kwon J; Rothberg PG; Marshall F; Block R; Dolan J; Mink JW;
    Dev Med Child Neurol; 2015 Apr; 57(4):366-71. PubMed ID: 25387857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan.
    Arntsen V; Strandheim J; Helland IB; Sand T; Brodtkorb E
    Epilepsy Behav; 2019 May; 94():59-64. PubMed ID: 30884409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the 'beyond epilepsy' project.
    Amadori E; Scala M; Cereda GS; Vari MS; Marchese F; Di Pisa V; Mancardi MM; Giacomini T; Siri L; Vercellino F; Serino D; Orsini A; Bonuccelli A; Bagnasco I; Papa A; Minetti C; Cordelli DM; Striano P
    Ital J Pediatr; 2020 Jul; 46(1):92. PubMed ID: 32631363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal ceroid lipofuscinosis type 2: an Australian case series.
    Johnson AM; Mandelstam S; Andrews I; Boysen K; Yaplito-Lee J; Fietz M; Nagarajan L; Rodriguez-Casero V; Ryan MM; Smith N; Scheffer IE; Ellaway C
    J Paediatr Child Health; 2020 Aug; 56(8):1210-1218. PubMed ID: 32329550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Symptoms and Treatment Outcomes in Neuronal Ceroid Lipofuscinosis Type 2: Croatian Experience.
    Radić Nišević J; Kolić I; Kostanjski M; Kovačević F; Prpić I
    J Pers Med; 2024 Jul; 14(8):. PubMed ID: 39201975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world.
    Lourenço CM; Pessoa A; Mendes CC; Rivera-Nieto C; Vergara D; Troncoso M; Gardner E; Mallorens F; Tavera L; Lizcano LA; Atanacio N; Guelbert N; Specola N; Mancilla N; de Souza CFM; Mole SE
    J Paediatr Child Health; 2021 Apr; 57(4):519-525. PubMed ID: 33377563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
    Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI in CLN2 disease patients: Subtle features that support an early diagnosis.
    Aydın K; Havali C; Kartal A; Serdaroğlu A; Haspolat Ş
    Eur J Paediatr Neurol; 2020 Sep; 28():228-236. PubMed ID: 32855042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.